KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases

References

• Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis. 2016;3:34.
   PubMedGoogle Scholar
• Szymanska M, Mahmood D, Yap TE, et al. Recent advancements in the medical treatment of diabetic retinal disease. Int J Mol Sci. 2021;22(17):9441.
   PubMed Web of Science ®Google Scholar
• Grzybowski A, Markeviciute A, Zemaitiene R. Treatment of macular edema in vascular retinal diseases: a 2021 update. J Clin Med. 2021;10(22):5300.
   PubMed Web of Science ®Google Scholar
• Patel SS, Naor J, Qudrat A, et al. Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durability. ARVO annual meeting abstract. July 2019. Invest Ophthalmol Vis Sci. 2019;60:3670.
   Web of Science ®Google Scholar
• American Academy of Ophthalmology. Basic and clinical science course, 2018-2019, retina and vitreous. 2019.
   Google Scholar
• Cheung CS, Wong AW, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthal. 2012;119(8):1609–1614.
   PubMed Web of Science ®Google Scholar
• Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2(1):17
   PubMedGoogle Scholar
• Laouri M, Chen E, Looman M, et al. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25(8):981–988.
   PubMed Web of Science ®Google Scholar
• Leung D, Cachianes G, Kuang W, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306–1309.
   PubMed Web of Science ®Google Scholar
• Ribatti D. The discovery of the fundamental role of VEGF in the development of the vascular system. Mech Dev. 2019;160:103579.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676.
   PubMed Web of Science ®Google Scholar
• Miller JW, Le Couter J, Strauss EC, et al. Vascular endothelial growth factor A in intraocular vascular disease. Ophthal. 2013;120(1):106–114.
   PubMed Web of Science ®Google Scholar
• Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001;276(10):7614–7620.
   PubMed Web of Science ®Google Scholar
• Hussain RM, Neiweem AE, Kansara V, et al. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019;28(10):861–869.
   PubMed Web of Science ®Google Scholar
• Hussain RM, Shaukat B, Ciulla LM, et al. Vascular endothelial growth factor antagonists: promising players in the treatment in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther. 2021;15:2653–2665.
   PubMed Web of Science ®Google Scholar
• McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654–661.
   PubMed Web of Science ®Google Scholar
• Fileta JB, Scott IU, Flynn HW. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthal Surg Laser Imaging Retina. 2014;45(2):143–149
   PubMed Web of Science ®Google Scholar
• Macugen FDA approval history. 2022. https://www.drugs.com/history/macugen.html. cited Feb 18, 2022.
   Google Scholar
• Baumal CR. Wet age-related macular degeneration: treatment advances to reduce the injection burden. Am J Manag Care. 2020;26(5 Suppl):S103–S111.
   PubMed Web of Science ®Google Scholar
• Lucentis FDA approval history. 2022. https://www.drugs.com/history/lucentis.html. cited Feb 18, 2022.
   Google Scholar
• Byooviz FDA approval history. 2022. https://www.drugs.com/history/byooviz.html. cited Feb 18, 2022.
   Google Scholar
• U.S. Food and Drug Administration. FDA approves first biosimilar to treat macular degeneration disease and other eye conditions. September 17, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treat-macular-degeneration-disease-and-other-eye-conditions. cited 2022 Feb 18
   Google Scholar
• Eylea FDA approval history. 2022. https://www.drugs.com/history/eylea.html. cited Feb 18, 2022.
   Google Scholar
• Beovu SJ FDA approval history. 2022. https://www.drugs.com/history/beovu.html. cited 2022 Feb 18
   Google Scholar
• Where the newest anti-VEGF agent fits in the exudative-disease toolbox. Retina Specialist. November 26, 2019. https://www.retina-specialist.com/article/where-the-newest-antivegf-agent-fits-in-the-exudativedisease-toolbox. cited 2022 Feb 18
   Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthal. 2020;127(1):72–84.
   PubMed Web of Science ®Google Scholar
• Witkin AJ, Hahn P, Murray TG, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020;4(4):269–279.
   PubMedGoogle Scholar
• Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion–Related events with brolucizumab: post Hoc Review of HAWK and HARRIER. Ophthal . 2021 July;128(7):1050–1059.
   PubMed Web of Science ®Google Scholar
• Susvimo SJ FDA approval history. 2022. https://www.drugs.com/history/susvimo.html. cited 2022 Feb 18
   Google Scholar
• Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized Phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthal. 2022;129(3):295.
   PubMed Web of Science ®Google Scholar
• Genentech’s HD. Susvimo receives FDA approval. Ophthalmology Times. October 22, 2021; https://www.ophthalmologytimes.com/view/fda-approves-genentech-s-susvimo. Accessed 2022 Feb 18.
   Google Scholar
• Vabysmo SJ FDA approval history. 2022. https://www.drugs.com/history/vabysmo.html. cited 2022 Feb 18
   Google Scholar
• Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. Published online ahead of print, January 21, 2022. Lancet. 2022;S0140-6736(22)00018–00026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00018-6/fulltext. Accessed 2022 Feb 18
   Google Scholar
• Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials Published online ahead of print, January 21, 2022. Lancet. 2022;S0140-6736(22)00010–00011. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00010-1/fulltext. Accessed 2022 Feb 18
   Google Scholar
• Williams GA IVT injections: health policy implications. June 5, 2014. https://www.reviewofophthalmology.com/article/ivt-injections-health-policy-implications. cited 2022 Feb 18
   Google Scholar
• Market Scope: Novartis leads the race to launch a new anti-VEGF for wet AMD. EyeWire. October 1, 2019. https://eyewire.news/articles/market-scope-novartis-leads-the-race-to-launch-a-new-anti-vegf-for-wet-amd/. cited 2022 Feb 18
   Google Scholar
• Maloney MH, Payne SR, Herrin J, et al. Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice. Ophthal. 2021;128(3):417–424.
   PubMed Web of Science ®Google Scholar
• Chandrasekaran PR, Madanagopalan VG. KSI-301: antibody biopolymer conjugate in retinal disorders. Ther Adv Ophthalmol. 2021;13:1–11.
   Web of Science ®Google Scholar
• Do DV. Extended durability in exudative retinal diseases using the novel intravitreal anti-VEGF antibody biopolymer conjugate KSI-301, Phase 1b study in patients with wAMD, DME and RVO, year 1 results. In: Angiogenesis, Exudation, and Degeneration. 2021; Feb. 13. KODIAK Sciences, http://ir.kodiak.com/static-files/b21b7da6-9a84-460a-a58a-5b5306c07abf
   Google Scholar
• Exploratory study to investigate the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics following single and multiple intravitreal administrations of KSI-301 in subjects with wAMD, DME and RVO. clinicaltrials.gov identifier: NCT03790852. Updated September 2, 2021. https://clinicaltrials.gov/ct2/show/NCT03790852. cited 2022 Feb 18
   Google Scholar
• A study to evaluate the efficacy and safety of KSI-301, an anti-VEGF antibody biopolymer conjugate, versus aflibercept in Patients with neovascular (wet) age-related macular degeneration. (DAZZLE). ClinicalTrials.gov identifier: NCT04049266. Updated November 19, 2020. https://clinicaltrials.gov/ct2/show/NCT04049266. cited 2022 Feb 18
   Google Scholar
• Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in patients with neovascular (Wet) age-related macular degeneration. PR Newswire. Published February 23, 2022. https://www.prnewswire.com/news-releases/kodiak-sciences-announces-top-line-results-from-its-initial-phase-2b3-study-of-ksi-301-in-patients-with-neovascular-wet-age-related-macular-degeneration-301488237.html. cited 2022 Mar 4
   Google Scholar
• Kodiak Sciences Announces First Quarter. Financial results and recent business highlights. PR newswire. May 10, 2021. https://www.prnewswire.com/news-releases/kodiak-sciences-announces-first-quarter-2021-financial-results-and-recent-business-highlights-301287302.html. cited 2022 Feb 19
   Google Scholar
• A study to evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with diabetic macular edema (DME) (GLIMMER). ClinicalTrials.gov identifier: NCT04603937. Updated Feb 16, 2021. https://clinicaltrials.gov/ct2/show/NCT04603937. cited 2022 Feb 18
   Google Scholar
• A trial to evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with diabetic macular edema (DME) (GLEAM). clinicaltrials.gov identifier: NCT04611152. Updated September 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04611152. cited 2022 Feb 18
   Google Scholar
• A study to evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in patients with macular edema due to retinal vein occlusion (RVO) (BEACON). ClinicalTrials.gov identifier: NCT04592419.Updated August 23, 2021. https://clinicaltrials.gov/ct2/show/NCT04592419. cited 2022 Feb 18
   Google Scholar
• A study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal aflibercept in participants with neovascular (wet) age-related macular degeneration (wAMD) (DAYLIGHT). ClinicalTrials.gov identifier: NCT04964089. Updated July 23, 2021. https://clinicaltrials.gov/ct2/show/NCT04964089. cited 2022 Feb 18
   Google Scholar
• A study to evaluate the efficacy and safety of intravitreal KSI-301in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) (GLOW). ClinicalTrials.gov identifier: NCT05066230. Updated January 20, 2022. https://www.clinicaltrials.gov/ct2/show/NCT05066230. cited 2022 Feb 18
   Google Scholar
• Adverum provides an update on ADVM-022 and the INFINITY trial in patients with diabetic macular edema. https://www.globenewswire.com/news-release/2021/07/22/2267699/32452/en/Adverum-Provides-Update-on-ADVM-022-and-the-INFINITY-Trial-in-Patients-with-Diabetic-Macular-Edema.html. Updated July 22, 2021. cited 2022 Feb 21
   Google Scholar